ALEX R. STAVROU, ESQUIRE
Stavrou & Frieg, P.A.
300 S. Hyde Park Ave.
Suite 180
Tampa, Florida 33606
Phone: (813) 251-1289
Fax: (813) 489-2528

April 18, 2016

OTC Markets Group
304 Hudson Street, 3rd Floor
New York, NY 10013

RE: Legal Opinion for CB Scientific, Inc. Regarding Adequate Current Information as to Annual Report for 2015 under OTCMarkets Reporting Requirements

This letter is rendered for OTC Markets Group Inc. ("OTC Markets Group") to rely upon in determining whether CB Scientific, Inc. (CBSC) has, in its Annual Report and Financials for the Year ended March 30, 2016, and the Annual Financial Statements for the year ending March 30, 2016 as posted on April 8, 2016, have made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. The undersigned counsel, Alex Stavrou, Esq., is a U.S. Citizen and has been retained by CBSC as independent counsel for the purpose of rendering this legal opinion letter and related matters.

The below signed counsel has examined such corporate records and other documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering of this letter. Such review included all documentation available on OTCMarkets.com, the SEC web site, and from the Corporation itself.

I am licensed to practice before all Florida state courts and the U.S. District Court, Middle District of Florida. I am permitted to practice before the Securities and Exchange Commission ("SEC") and have never been prohibited from practice in any jurisdiction or court.

I have not relied upon the work of any other counsel in the preparation of this letter.

In preparing this legal opinion, I have relied upon communications and interviews of Sam Talari, President and CEO. In my opinion, and to the best of my

knowledge, the above individuals were credible and reliable, as was all the information they provided.

In preparing this opinion, I reviewed the following documents:

1. CBSC Original Articles of Incorporation
2. CBSC Certificate of Incorporation
3. CBSC By-Laws
4. Designation of Preferred Shares Series A and B.
5. Secretary of State information available from state of domicile.
6. Corporate Minutes of the Board of Directors and Shareholders
7. Annual Report, for year ending March 30, 2016, filed April 8, 2016.
8. Quarterly Report for period ending December 31, 2016, as filed March 13, 2016.

At present, "adequate public information" is available concerning the securities, as that term has been defined in Rule 144(c)(2) of the Securities Act; includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); complies as to form with the OTC Markets Group's Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcmarkets.com; and has been posted through the OTC Disclosure and News Service, as certified by Sam Talari, CEO.

The party responsible for the preparation of the financial statements of the issuer is:

Turner, Stone & Company, L.L.P.
12700 Park Central Drive Suite 1400 Dallas, TX 75251

The Fiscal Year End for CBSC is March 30th.

CBSC's transfer agent is:

ClearTrust, LLC 16540
Pointe Village Dr.
Suite 206
Lutz, FL 33558

This transfer agent is registered with the SEC. In order to confirm the number of outstanding shares, I asked the Issuer to cause the transfer agent to send a current stockholder's list and to confirm in writing the number of shares outstanding. On April 18, 2016 Cleartrust provided a current shareholder report and confirmed there were 57,105,263 shares outstanding.

I have personally met with management and the directors; I have reviewed the information, as amended published by the Issuer through the OTC Disclosure and News Services; and discussed the Information with management and the director majority.

After inquiry of management and director majority, I have been informed and have investigated both myself and through Company counsel have related that no person, including to the best of my knowledge no individual in management or director of the Issuer, nor any other 5% or greater holder, nor the undersigned is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

The Company has not, by representation of the Corporate Officers and Directors, and by independent investigation of the below signed counsel, been the subject of any promotional activities in the past year.

Counsel has made specific inquiry of each of the officers and directors, and based upon such inquiries and other information available to counsel, any sales of the Securities by Insiders within the twelve-month period prior to the opinion have been made in compliance with Rule 144, including, without limitation, any required filings of Form 144, and nothing has come to the attention of counsel indicating that any of the Insiders is in possession of any material non-public information regarding the Issuer or the Securities that would prohibit any of them from buying or selling the Securities under Rules 10b-5 or 10b5-1 under the Exchange Act.

No person other than OTC Markets Group is entitled to rely on this legal review. I hereby grant OTC Markets Group full and complete permission and rights to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators.

I do not express any opinion herein concerning any law other than the laws of the United States and the jurisdictions where I am permitted to render opinions. I hereby furnish this opinion solely for the benefit of OTCMarkets and the Issuer. This opinion is therefore to be used for that sole purpose. I do not assume, nor imply, any responsibility or obligation to make updates to this opinion beyond the date of this letter.

The undersigned has performed an inquiry as to whether CBSC was involved in any promotional activities, and confirmed that it has not been.

For questions or issues concerning this legal opinion and review, please contact me at the address and phone number listed above.

Sincerely,

Alex Stavrou, Esquire